{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:37:13Z","timestamp":1787503033581,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40272-023-00573-y","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:01:50Z","timestamp":1685750510000},"page":"467-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Macitentan in the Young\u2014Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease\u00a0treated in a Pediatric Tertiary Care Center"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0256-7145","authenticated-orcid":false,"given":"Sulaima","family":"Albinni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Heno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"Pavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Kitzmueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Michel-Behnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,3]]},"reference":[{"key":"573_CR1","doi-asserted-by":"publisher","first-page":"1801916","DOI":"10.1183\/13993003.01916-2018","volume":"53","author":"EB Rosenzweig","year":"2019","unstructured":"Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et\u00a0al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J [Internet]. 2019;53:1801916. https:\/\/doi.org\/10.1183\/13993003.01916-2018.","journal-title":"Eur Respir J [Internet]."},{"key":"573_CR2","doi-asserted-by":"publisher","unstructured":"Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012;379(9815):537\u2013546. https:\/\/doi.org\/10.1016\/S0140-6736(11)61621-8. Accessed 30 Sept 2022.","DOI":"10.1016\/S0140-6736(11)61621-8"},{"key":"573_CR3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.healun.2019.06.022","volume":"38","author":"G Hansmann","year":"2019","unstructured":"Hansmann G, Koestenberger M, Alastalo T-P, Apitz C, Austin ED, Bonnet D, et\u00a0al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2019;38:879\u2013901.","journal-title":"J Heart Lung Transplant Off Publ Int Soc Heart Transplant."},{"key":"573_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et\u00a0al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J [Internet]. 2022. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237.","journal-title":"Eur Heart J [Internet]."},{"key":"573_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4103\/2045-8932.83456","volume":"1","author":"MJ del Cerro","year":"2011","unstructured":"del Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et\u00a0al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011;1:286\u201398. https:\/\/doi.org\/10.4103\/2045-8932.83456.","journal-title":"Pulm Circ."},{"key":"573_CR6","doi-asserted-by":"publisher","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","volume":"62","author":"RM Tuder","year":"2013","unstructured":"Tuder RM, Archer SL, Peter D, Erzurum SC, Christophe G, Evangelos M, et\u00a0al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D4-12. https:\/\/doi.org\/10.1016\/j.jacc.2013.10.025.","journal-title":"J Am Coll Cardiol"},{"key":"573_CR7","doi-asserted-by":"crossref","unstructured":"Lang IM, Bonderman D, Kneussl M, Marx M. Paediatric pulmonary vascular disease. Paediatr Respir Rev [Internet]. 2004 [cited 2019 Apr 13];5:238\u201348. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152605420400048X.","DOI":"10.1016\/j.prrv.2004.04.008"},{"key":"573_CR8","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2014.02.575","volume":"63","author":"WMH Zijlstra","year":"2014","unstructured":"Zijlstra WMH, Douwes JM, Rosenzweig EB, Schokker S, Krishnan U, Roofthooft MTR, et\u00a0al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol. 2014;63:2159\u201369.","journal-title":"J Am Coll Cardiol"},{"key":"573_CR9","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1136\/hrt.2009.182378","volume":"96","author":"S Moledina","year":"2010","unstructured":"Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart [Internet]. 2010;96:1401\u20136. https:\/\/doi.org\/10.1136\/hrt.2009.182378.","journal-title":"Heart [Internet]."},{"issue":"Suppl 3","key":"573_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2362.2006.01681.x","volume":"36","author":"M Beghetti","year":"2006","unstructured":"Beghetti M. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. Eur J Clin Invest. 2006;36(Suppl 3):16\u201324.","journal-title":"Eur J Clin Invest"},{"key":"573_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40272-019-00374-2","volume":"22","author":"CM Avitabile","year":"2020","unstructured":"Avitabile CM, Vorhies EE, Ivy DD. Drug treatment of pulmonary hypertension in children. Paediatr Drugs. 2020;22:123\u201347.","journal-title":"Paediatr Drugs"},{"key":"573_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et\u00a0al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J [Internet]. 2016;37:67\u2013119. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317.","journal-title":"Eur Heart J [Internet]."},{"key":"573_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Gali\u00e8 N, Ghofrani H-A, et\u00a0al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med [Internet]. 2013;369:809\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1213917.","journal-title":"N Engl J Med [Internet]."},{"key":"573_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1517\/14740338.2014.859674","volume":"13","author":"J Dingemanse","year":"2014","unstructured":"Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf [Internet]. 2014;13:391\u2013405. https:\/\/doi.org\/10.1517\/14740338.2014.859674.","journal-title":"Expert Opin Drug Saf [Internet]."},{"key":"573_CR15","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1124\/jpet.108.142976","volume":"327","author":"M Iglarz","year":"2008","unstructured":"Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, et\u00a0al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther [Internet]. 2008;327:736\u201345. https:\/\/doi.org\/10.1124\/jpet.108.142976.","journal-title":"J Pharmacol Exp Ther [Internet]."},{"key":"573_CR16","doi-asserted-by":"crossref","unstructured":"Aypar E, Alehan D, Karag\u00f6z T, Aykan HH, Ertugrul \u0130. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. Cardiol Young [Internet]. 2018;28:542\u20137. https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951117002542\/type\/journal_article. Accessed 20 April 2022.","DOI":"10.1017\/S1047951117002542"},{"key":"573_CR17","doi-asserted-by":"crossref","unstructured":"Flores M, Caro AT, Mendoza A. Initial experience in children with the use of macitentan in pulmonary arterial hypertension after side effects with other endothelin receptor antagonists. Prog Pediatr Cardiol [Internet]. 2019;52:55\u20136. http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1058981318300341. Accessed 20 April 2022","DOI":"10.1016\/j.ppedcard.2018.11.004"},{"key":"573_CR18","doi-asserted-by":"crossref","unstructured":"Safdar Z, Thakur A, Frost A. Tolerability of switch to macitentan from bosentan in pulmonary arterial hypertension. South Med J [Internet]. 2017;110:223\u20138. http:\/\/sma.org\/southern-medical-journal\/article\/tolerability-switch-macitentan-bosentan-pulmonary-arterial-hypertension. Accessed 20 April 2022","DOI":"10.14423\/SMJ.0000000000000607"},{"key":"573_CR19","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.21037\/cdt.2020.04.01","volume":"10","author":"S Schweintzger","year":"2020","unstructured":"Schweintzger S, Koestenberger M, Schlagenhauf A, Grangl G, Burmas A, Kurath-Koller S, et\u00a0al. Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. Cardiovasc Diagn Ther. 2020;10:1675\u201385.","journal-title":"Cardiovasc Diagn Ther."},{"key":"573_CR20","doi-asserted-by":"publisher","first-page":"204589402097950","DOI":"10.1177\/2045894020979503","volume":"11","author":"S Albinni","year":"2021","unstructured":"Albinni S, Pavo I, Kitzmueller E, Michel-Behnke I. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues \u2013 a single-centre experience. Pulm Circ. 2021;11:2045894020979503. https:\/\/doi.org\/10.1177\/2045894020979503.","journal-title":"Pulm Circ"},{"key":"573_CR21","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00246-012-0306-8","volume":"33","author":"RD Ross","year":"2012","unstructured":"Ross RD. The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatr Cardiol. 2012;33:1295\u2013300.","journal-title":"Pediatr Cardiol"},{"key":"573_CR22","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/j.1460-9592.2009.03140.x","volume":"19","author":"OO Nafiu","year":"2009","unstructured":"Nafiu OO, Voepel-Lewis T, Morris M, Chimbira WT, Malviya S, Reynolds PI, et\u00a0al. How do pediatric anesthesiologists define intraoperative hypotension? Paediatr Anaesth. 2009;19:1048\u201353.","journal-title":"Paediatr Anaesth"},{"key":"573_CR23","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1164\/rccm.200604-547OC","volume":"174","author":"PR Forfia","year":"2006","unstructured":"Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et\u00a0al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med [Internet]. 2006;174:1034\u201341. https:\/\/doi.org\/10.1164\/rccm.200604-547OC.","journal-title":"Am J Respir Crit Care Med [Internet]"},{"key":"573_CR24","doi-asserted-by":"crossref","unstructured":"Koestenberger M, Ravekes W, Everett AD, Stueger HP, Heinzl B, Gamillscheg A, et al. right ventricular function in infants, children and adolescents: reference values of the tricuspid annular plane systolic excursion (TAPSE) in 640 healthy patients and calculation of z score values. J Am Soc Echocardiogr [Internet]. 2009;22:715\u20139. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0894731709003083. Accessed 20 Oct 2022","DOI":"10.1016\/j.echo.2009.03.026"},{"key":"573_CR25","doi-asserted-by":"crossref","unstructured":"Abbas AE, Franey LM, Marwick T, Maeder MT, Kaye DM, Vlahos AP, et al. Noninvasive assessment of pulmonary vascular resistance by Doppler echocardiography. J Am Soc Echocardiogr [Internet]. 2013;26:1170\u20137. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0894731713004458. Accessed 20 Oct 2022","DOI":"10.1016\/j.echo.2013.06.003"},{"key":"573_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1164\/rccm.201004-0601OC","volume":"183","author":"JS Arkles","year":"2011","unstructured":"Arkles JS, Opotowsky AR, Ojeda J, Rogers F, Liu T, Prassana V, et\u00a0al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med. 2011;183:268\u201376.","journal-title":"Am J Respir Crit Care Med"},{"key":"573_CR27","doi-asserted-by":"crossref","unstructured":"Opotowsky AR, Clair M, Afilalo J, Landzberg MJ, Waxman AB, Moko L, et al. A Simple echocardiographic method to estimate pulmonary vascular resistance. Am J Cardiol [Internet]. 2013;112:873\u201382. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914913011296. Accessed 20 Oct 2022","DOI":"10.1016\/j.amjcard.2013.05.016"},{"key":"573_CR28","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.21037\/cdt-21-119","volume":"11","author":"AE Lammers","year":"2021","unstructured":"Lammers AE, Apitz C, Michel-Behnke I, Koestenberger M. A guide to echocardiographic assessment in children and adolescents with pulmonary hypertension. Cardiovasc Diagn Ther. 2021;11:1160\u201377.","journal-title":"Cardiovasc Diagn Ther."},{"key":"573_CR29","doi-asserted-by":"crossref","unstructured":"Chemla D, Castelain V, Humbert M, H\u00e9bert J-L, Simonneau G, Lecarpentier Y, et\u00a0al. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest [Internet]. 2004 [cited 2022 Apr 10];126:1313\u20137. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236921531312X.","DOI":"10.1378\/chest.126.4.1313"},{"key":"573_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.echo.2013.01.006","volume":"26","author":"RC Steckelberg","year":"2013","unstructured":"Steckelberg RC, Tseng AS, Nishimura R, Ommen S, Sorajja P. Derivation of mean pulmonary artery pressure from noninvasive parameters. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2013;26:464\u20138.","journal-title":"J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr."},{"key":"573_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/eurheartj\/ehx025","volume":"38","author":"N Gali\u00e8","year":"2017","unstructured":"Gali\u00e8 N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani H-A, et\u00a0al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017;38:1147\u201355. Accessed 12 Dec 2022","journal-title":"Eur Heart J"},{"key":"573_CR32","doi-asserted-by":"crossref","unstructured":"Aypar E, Alehan D, Karag\u00f6z T, Aykan H, Ertugrul \u0130. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results. Cardiol Young [Internet]. 2020;30:681\u20135. https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951120000773\/type\/journal_article.","DOI":"10.1017\/S1047951120000773"},{"key":"573_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/ejechocard\/jer235","volume":"13","author":"A L\u00f3pez-Candales","year":"2012","unstructured":"L\u00f3pez-Candales A, Edelman K. Shape of the right ventricular outflow Doppler envelope and severity of pulmonary hypertension. Eur Heart J Cardiovasc Imaging [Internet]. 2012;13:309\u201316. https:\/\/doi.org\/10.1093\/ejechocard\/jer235.","journal-title":"Eur Heart J Cardiovasc Imaging [Internet]."},{"key":"573_CR34","doi-asserted-by":"publisher","first-page":"204589321774142","DOI":"10.1177\/2045893217741429","volume":"8","author":"V Nadeau","year":"2018","unstructured":"Nadeau V, Potus F, Boucherat O, Paradis R, Tremblay E, Iglarz M, et\u00a0al. Dual ETA\/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulm Circ. 2018;8:2045893217741429.","journal-title":"Pulm Circ."},{"key":"573_CR35","doi-asserted-by":"crossref","unstructured":"Langleben D, Orfanos SE, Fox BD, Messas N, Giovinazzo M, Catravas JD. The paradox of pulmonary vascular resistance: restoration of pulmonary capillary recruitment as a sine qua non for true therapeutic success in pulmonary arterial hypertension. J Clin Med [Internet]. 2022;11:4568. https:\/\/www.mdpi.com\/2077-0383\/11\/15\/4568.","DOI":"10.3390\/jcm11154568"},{"key":"573_CR36","doi-asserted-by":"crossref","unstructured":"Brittain EL, Pugh ME, Wheeler LA, Robbins IM, Loyd JE, Newman JH, et\u00a0al. Prostanoids but not oral therapies improve\u00a0right ventricular function in pulmonary arterial hypertension. JACC Heart Fail [Internet]. 2013;1:300\u20137. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213177913001893. Accessed 12 Dec 2022","DOI":"10.1016\/j.jchf.2013.05.004"},{"key":"573_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/FJC.0000000000000296","volume":"66","author":"M Iglarz","year":"2015","unstructured":"Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, et\u00a0al. Comparison of macitentan and bosentan on right ventricular remodeling in a rat model of non-vasoreactive pulmonary hypertension. J Cardiovasc Pharmacol. 2015;66:457.","journal-title":"J Cardiovasc Pharmacol"},{"key":"573_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jcmg.2021.07.027","volume":"15","author":"VN Anton","year":"2022","unstructured":"Anton VN, Richard C, Emmanuelle C, Kiely David G, Tim MJ, Nicolas M, et\u00a0al. The REPAIR Study. JACC Cardiovasc Imaging [Internet]. 2022;15:240\u201353. https:\/\/doi.org\/10.1016\/j.jcmg.2021.07.027.","journal-title":"JACC Cardiovasc Imaging [Internet]"},{"key":"573_CR39","doi-asserted-by":"crossref","unstructured":"Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, et\u00a0al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol [Internet]. 2005 [cited 2019 Apr 13];46:697\u2013704. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109705011964.","DOI":"10.1016\/j.jacc.2005.01.066"},{"key":"573_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijcard.2007.04.078","volume":"127","author":"MA Gatzoulis","year":"2008","unstructured":"Gatzoulis MA, Beghetti M, Gali\u00e8 N, Granton J, Berger RMF, Lauer A, et\u00a0al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127:27\u201332. Accessed 10 April 2022","journal-title":"Int J Cardiol"},{"key":"573_CR41","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/hrt.2006.100388","volume":"93","author":"SC Apostolopoulou","year":"2007","unstructured":"Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart [Internet]. 2007;93:350\u20134. https:\/\/doi.org\/10.1136\/hrt.2006.100388.","journal-title":"Heart [Internet]."},{"key":"573_CR42","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/heartjnl-2017-311876","volume":"104","author":"C Arnott","year":"2018","unstructured":"Arnott C, Strange G, Bullock A, Kirby AC, O\u2019Donnell C, Radford DJ, et\u00a0al. Pulmonary vasodilator therapy is associated with greater survival in Eisenmenger syndrome. Heart [Internet]. 2018;104:732\u20137. https:\/\/doi.org\/10.1136\/heartjnl-2017-311876.","journal-title":"Heart [Internet]."},{"key":"573_CR43","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","volume":"73","author":"RJ Barst","year":"2003","unstructured":"Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et\u00a0al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73:372\u201382.","journal-title":"Clin Pharmacol Ther"},{"key":"573_CR44","doi-asserted-by":"crossref","unstructured":"Wacker J, Weintraub RG. Macitentan in pulmonary arterial hypertension associated with congenital heart defects. Heart Lung Circ [Internet]. 2017;26:1006\u20137. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950617313318.","DOI":"10.1016\/j.hlc.2017.08.003"},{"key":"573_CR45","doi-asserted-by":"crossref","unstructured":"Herbert S, Gin-Sing W, Howard L, Tulloh RMR. Early Experience of macitentan for pulmonary arterial hypertension in adult congenital heart disease. Heart Lung Circ [Internet]. 2017;26:1113\u20136. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950617300318.","DOI":"10.1016\/j.hlc.2016.12.011"},{"key":"573_CR46","doi-asserted-by":"crossref","unstructured":"Blok IM, van Riel ACMJ, van Dijk APJ, Mulder BJM, Bouma BJ. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement? Int J Cardiol [Internet]. 2017;227:51\u20132. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316336907","DOI":"10.1016\/j.ijcard.2016.11.211"},{"key":"573_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.118.033575","volume":"139","author":"MA Gatzoulis","year":"2019","unstructured":"Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, et\u00a0al. Evaluation of macitentan in patients with Eisenmenger syndrome: results from the randomized, controlled MAESTRO Study. Circulation [Internet]. 2019;139:51\u201363. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.033575.","journal-title":"Circulation [Internet]."},{"key":"573_CR48","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1183\/09059180.00007714","volume":"23","author":"M Beghetti","year":"2014","unstructured":"Beghetti M, Berger RMF. The challenges in paediatric pulmonary arterial hypertension. Eur Respir Rev [Internet]. 2014;23:498\u2013504. https:\/\/doi.org\/10.1183\/09059180.00007714. Accessed 08 May 2022","journal-title":"Eur Respir Rev [Internet]"},{"key":"573_CR49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/157016109787455653","volume":"7","author":"M Beghetti","year":"2009","unstructured":"Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol. 2009;7:225\u201333. Accessed 08 May 2022","journal-title":"Curr Vasc Pharmacol"},{"key":"573_CR50","doi-asserted-by":"crossref","unstructured":"Ivy DD, Abman SH, Barst RJ, Berger RMF, Bonnet D, Fleming TR, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol [Internet]. 2013;62:D117\u201326. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713058713. Accessed 18 Mar 2023","DOI":"10.1016\/j.jacc.2013.10.028"},{"key":"573_CR51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1183\/09031936.00053510","volume":"38","author":"AA Hislop","year":"2011","unstructured":"Hislop AA, Moledina S, Foster H, Schulze-Neick I, Haworth SG. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J [Internet]. 2011;38:70\u20137. https:\/\/doi.org\/10.1183\/09031936.00053510.","journal-title":"Eur Respir J [Internet]."},{"key":"573_CR52","doi-asserted-by":"crossref","unstructured":"Yamamura K, Nagata H, Ikeda K, Ihara K, Hara T. Efficacy of bosentan therapy for segmental pulmonary artery hypertension due to major aortopulmonary collateral arteries in children. Int J Cardiol [Internet]. 2012;161:e1\u20133. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527312002264.","DOI":"10.1016\/j.ijcard.2012.03.021"},{"key":"573_CR53","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00246-015-1278-2","volume":"37","author":"EK Grant","year":"2016","unstructured":"Grant EK, Berger JT. Use of pulmonary hypertension medications in patients with tetralogy of fallot with pulmonary atresia and multiple aortopulmonary collaterals. Pediatr Cardiol [Internet]. 2016;37:304\u201312. https:\/\/doi.org\/10.1007\/s00246-015-1278-2.","journal-title":"Pediatr Cardiol [Internet]"},{"key":"573_CR54","doi-asserted-by":"crossref","unstructured":"Schuuring MJ, Bouma BJ, Cordina R, Gatzoulis MA, Budts W, Mullen MP, et al. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. Int J Cardiol [Internet]. 2013;164:106\u201310. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527311006243. Accessed 04 Nov 2022","DOI":"10.1016\/j.ijcard.2011.06.084"},{"key":"573_CR55","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1017\/S1047951117001548","volume":"27","author":"SC Apostolopoulou","year":"2017","unstructured":"Apostolopoulou SC, Vagenakis G, Rammos S. Pulmonary vasodilator therapy in tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals: case series and review of literature. Cardiol Young. 2017;27:1861\u20134.","journal-title":"Cardiol Young"},{"key":"573_CR56","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1086\/685102","volume":"6","author":"MJ Cerro","year":"2016","unstructured":"Cerro MJ, Moledina S, Haworth SG, Ivy D, Dabbagh MA, Banjar H, et\u00a0al. Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the pulmonary vascular research institute, pediatric and congenital heart disease task forces. Pulm Circ [Internet]. 2016;6:118\u201325. https:\/\/doi.org\/10.1086\/685102. Accessed 20 Nov 2022","journal-title":"Pulm Circ [Internet]"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00573-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-023-00573-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00573-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:25:46Z","timestamp":1687339546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-023-00573-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1007\/s40272-023-00573-y","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"23 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Medical University of Vienna.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sulaima Albinni, Julian Heno, Imre Pavo, Erwin Kitzmueller, Manfred Marx, and Ina Michel-Behnke declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the local Ethics Comittee of the Medical University of Vienna (local ethics number 1619\/2018).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Oral and written\u00a0informed consent was obtained from all patients and caregivers before treatment initiation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Data analyzed during this study are included in this published article as supplementary information files. Additional patients\u2019 data are available from the corresponding author on request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Sulaima Albinni wrote the manuscript and was responsible for study design and conduction. Julian Heno performed the statistical analysis and contributed to the final manuscript. Imre Pavo was responsible for material preparation and data collection. Erwin Kitzmueller did the hemodynamic measurements and participated in research coordination. Manfred Marx contributed to interpretation and analysis of the data and reviewed the manuscript. Ina Michel-Behnke was responsible for study conduct and hemodynamic measurements and contributed to the final writing of this manuscript. All authors read and approved the final version.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}